Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside

Area of Science:

• Nuclear Medicine
• Radiochemistry
• Oncology

Background:

• Targeted radionuclide therapy (TRNT) offers a systemic approach to cancer treatment, irradiating primary tumors and metastases.
• Unlike external beam therapies, TRNT aims to minimize damage to healthy tissues.
• Alpha-emitting radionuclides, such as bismuth-213 (213Bi), are being explored for their therapeutic potential.

Purpose of the Study:

• To review the benefits and drawbacks of targeted alpha therapy using 213Bi.
• To provide a comprehensive overview from radionuclide production to clinical application.
• To discuss the future perspectives of 213Bi in cancer treatment.

Main Methods:

• Review of radionuclide properties and production of 225Ac and 213Bi.
• Discussion of bismuth's fundamental chemical properties.
• Overview of bifunctional chelators and radiopharmaceutical design considerations for bismuth.
• Summary of preclinical and clinical studies involving 213Bi-radiopharmaceuticals.

Main Results:

• 213Bi exhibits promising properties for targeted alpha therapy.
• Various acyclic and macrocyclic bifunctional chelators are available for bismuth complexation.
• Preclinical and clinical studies demonstrate the potential of 213Bi-based radiopharmaceuticals.

Conclusions:

• 213Bi represents a potential 'magic bullet' for targeted radionuclide therapy.
• Further research and clinical studies are warranted to fully realize the potential of 213Bi-based cancer treatments.
• The development of effective 213Bi-radiopharmaceuticals is crucial for advancing this therapeutic option.